Versant Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Versant Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-107	Closed	–	–	1711
2019 Q3	$0	Hold	107	–	–	﹤0.01%	1715
2019 Q2	$0	Buy	+107	New	+$407	﹤0.01%	1854
2018 Q1	–	Sell	-4	Closed	–	–	1739
2017 Q4	$0	Buy	+4	New	+$296	﹤0.01%	1708

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Versant Capital Management's MLNT Position: Q4 2019 in Review

Versant Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 107 shares.

Versant Capital Management first reported a position in MLNT in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2019. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Versant Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Versant Capital Management sold 107 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019.
Versant Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
Versant Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2019.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Versant Capital Management's 13F filing for Q4 2019, filed 28 Jan 2020.